高危前列腺癌大分割剂量递增放疗:前列腺癌研究-5(PCS-5)生存分析,一项由GROUQ主导的III期试验
PCS5是一项加拿大 multicenter、开放标签、III期随机对照试验,比较常规分割放疗(CFRT)与大分割放疗(HFRT)在高危前列腺癌患者中的生存结局。中位随访5年时,两组总生存、前列腺癌特异性生存、生化复发无生存及无远处转移生存均无显著差异。作者认为HFRT(68 Gy/25次)联合盆腔淋巴结放疗和长期雄激素抑制应考虑为高危前列腺癌外照射放疗的新标准治疗。
要点
- PCS5纳入329例高危前列腺癌患者,随机1:1接受CFRT或HFRT,中位随访5年。
- 两组OS、PCSS、BCRFS、DMFS均无显著差异,风险比置信区间均跨1。
- 作者认为HFRT(68 Gy/25次)联合盆腔淋巴结放疗和长期雄激素抑制应考虑为新标准治疗。
核心结论
- HFRT(68 Gy/25次)与CFRT(76 Gy/38次)在生存结局上无差异。
- 作者认为HFRT联合盆腔淋巴结放疗和长期雄激素抑制应考虑为高危前列腺癌外照射放疗的新标准治疗。
研究设计与样本
- PCS5为加拿大 multicenter、开放标签、III期随机对照试验。
- 纳入组织学证实、临床局限但具有一项或以上高危特征(T3/T4、Gleason评分≥8、前列腺特异性抗原>20)的前列腺癌男性。
- 患者按1:1随机接受CFRT(前列腺76 Gy/38次,盆腔淋巴结46 Gy/23次)或HFRT(前列腺68 Gy/25次,盆腔淋巴结45 Gy/25次),并接受28个月雄激素抑制。
- 共329例患者随机,HFRT组164例、CFRT组165例,生存分析分别纳入159例和160例。
- 主要终点为毒性,次要终点包括生存结局。
主要发现
- 中位随访5年时,总生存率HFRT组90.3% vs CFRT组89.7%(RR 1.01,95%CI 0.93-1.09)。
- 前列腺癌特异性生存率HFRT组97.4% vs CFRT组97.5%(RR 1.00,95%CI 0.93-1.07)。
- 生化复发无生存率HFRT组85.2% vs CFRT组85.2%(RR 1.00,95%CI 0.91-1.10)。
- 无远处转移生存率HFRT组87.1% vs CFRT组87.1%(RR 1.00,95%CI 0.92-1.09)。
- 风险比:OS 0.92(95%CI 0.56-1.53),PCSS 1.31(95%CI 0.46-3.78),BCRFS 0.85(95%CI 0.56-1.30),DMFS 0.90(95%CI 0.56-1.43)。
关键数值与推荐
- 高危特征定义:T3/T4、Gleason评分≥8、前列腺特异性抗原>20。
- CFRT方案:前列腺76 Gy/38次,盆腔淋巴结46 Gy/23次。
- HFRT方案:前列腺68 Gy/25次,盆腔淋巴结45 Gy/25次。
- 两组均接受28个月雄激素抑制。
临床怎么用
- 作者认为HFRT(68 Gy/25次)联合盆腔淋巴结放疗和长期雄激素抑制应考虑为高危前列腺癌外照射放疗的新标准治疗。
局限性
- 样本量是限制因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Prostate Cancer Study 5 (PCS5) compared conventional fractionated radiotherapy (CFRT) with hypofractionated radiotherapy (HFRT) in high-risk prostate cancer (PCa) patients, hypothesizing similar toxicity and survival outcomes. This report presents the efficacy analysis. METHODS: PCS5 is a Canadian multicenter, open-label, phase 3 randomized control trial. Men with histologically proven, clinically localized PCa with one or more high-risk features (T3/T4, Gleason score ≥8, and prostate-specific antigen >20) were eligible. Patients were randomized 1:1 to CFRT (76 Gy/38 fractions [Fx] to the prostate and 46 Gy/23 Fx to the pelvic lymph nodes [PLNs]) or HFRT (68 Gy/25 Fx to the prostate and 45 Gy/25 Fx to the PLNs) and 28 mo of androgen suppression. The primary endpoint was toxicity; secondary endpoints included survival outcomes. KEY FINDINGS AND LIMITATIONS: Of 329 patients, 164 were randomized to HFRT and 165 to CFRT, with 159 in the HFRT arm and 160 in the CFRT arm included in survival analyses. At the 5-yr median follow-up, there were no significant differences in overall survival (OS; 90.3% vs 89.7%; risk ratio [RR]: 1.01; 95% confidence interval [CI]: 0.93-1.09), PCa-specific survival (PCSS; 97.4% vs 97.5%; RR: 1.00; 95% CI: 0.93-1.07), biochemical recurrence-free survival (BCRFS; 85.2% vs 85.2%; RR: 1.00; 95% CI: 0.91-1.10), or distant metastasis-free survival (DMFS; 87.1% vs 87.1%; RR: 1.00; 95% CI: 0.92-1.09). Hazard ratios were 0.92 (95% CI: 0.56-1.53) for OS, 1.31 (95% CI: 0.46-3.78) for PCSS, 0.85 (95% CI: 0.56-1.30) for BCRFS, and 0.90 (95% CI: 0.56-1.43) for DMFS. Sample size was a limiting factor. CONCLUSIONS AND CLINICAL IMPLICATIONS: There were no differences in survival outcomes between HFRT (68 Gy/25 Fx) and CFRT (76 Gy/38 Fx). HFRT, including PLN radiotherapy and long-term androgen deprivation therapy, should be considered a new standard of care for high-risk PCa patients undergoing external beam radiotherapy.
引用
- Niazi T, Nabid A, Malagon T, et al. Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial. Eur Urol. 2024. PMID: 39271420. doi:10.1016/j.eururo.2024.08.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。